Model‐based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?
Statistics in Medicine · 2024
DOI: 10.1002/sim.10088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Statistics in Medicine, 2024. Verfasst von Morgane Philipp und 10 weiteren Autor:innen. Beteiligte Einrichtung: Université Paris Cité, IAME, INSERM, Paris, France. Hauptthemen laut MEDLINE: Therapeutic Equivalency, Computer Simulation, Cross-Over Studies, Models, Statistical. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: U.S. Food and Drug Administration.
Abstract (Originalsprache)
Conventional pharmacokinetic (PK) bioequivalence (BE) studies aim to compare the rate and extent of drug absorption from a test (T) and reference (R) product using non‐compartmental analysis (NCA) and the two one‐sided test (TOST). Recently published regulatory guidance recommends alternative model‐based (MB) approaches for BE assessment when NCA is challenging, as for long‐acting injectables and products which require sparse PK sampling. However, our previous research on MB‐TOST approaches showed that model misspecification can lead to inflated type I error. The objective of this research was to compare the performance of model selection (MS) on R product arm data and model averaging (MA) from a pool of candidate structural PK models in MBBE studies with sparse sampling. Our simulation study was inspired by a real case BE study using a two‐way crossover design. PK data were simulated using three structural models under the null hypothesis and one model under the alternative hypothesis. MB‐TOST was applied either using each of the five candidate models or following MS and MA with or without the simulated model in the pool. Assuming T and R have the same PK model, our simulation shows that following MS and MA, MB‐TOST controls type I error rates at or below 0.05 and attains similar or even higher power than when using the simulated model. Thus, we propose to use MS prior to MB‐TOST for BE studies with sparse PK sampling and to consider MA when candidate models have similar Akaike information criterion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Université Paris Cité, IAME, INSERM, Paris, France.
- Clinical Pharmacometrics, Quantitative Pharmacology, Servier, Suresnes, France.
- Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Office of Biostatistics, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
ORCID-Profile: Morgane Philipp
Förderung
- U.S. Food and Drug Administration
Zitieren
APA
Philipp, M., Tessier, A., Donnelly, M., Fang, L., Feng, K., Zhao, L., Grosser, S., Sun, G., Sun, W., Mentré, F., & Bertrand, J. (2024). Model‐based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?. Statistics in Medicine. https://doi.org/10.1002/sim.10088
Vancouver
Philipp M, Tessier A, Donnelly M, Fang L, Feng K, Zhao L, et al. Model‐based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?. Statistics in Medicine. 2024. doi:10.1002/sim.10088
BibTeX
@article{Philipp2024,
author = {Philipp, Morgane and Tessier, Adrien and Donnelly, Mark and Fang, Lanyan and Feng, Kairui and Zhao, Liang and Grosser, Stella and Sun, Guoying and Sun, Wanjie and Mentré, France and Bertrand, Julie},
title = {Model‐based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?},
journal = {Statistics in Medicine},
year = {2024},
doi = {10.1002/sim.10088}
}
EUVIMED